Eyelid ptosis after botulinum toxin is a temporary drooping of the upper lid caused by toxin diffusing to the levator palpebrae superioris. It is best prevented by precise placement, conservative dosing and patient selection. When it occurs, practitioners commonly manage it with alpha-adrenergic eye drops such as apraclonidine 0.5% while it resolves, usually within weeks.
Key Takeaways
- Eyelid ptosis is a recognised, usually reversible complication of botulinum toxin type A, typically appearing within the first one to two weeks.
- Prevention rests on anatomy knowledge: stay away from the orbital margin, keep to the mid-pupillary line, and balance glabellar and forehead dosing.
- Apraclonidine 0.5% is the most commonly cited drop; oxymetazoline 0.1% is FDA-approved for acquired blepharoptosis.
- Pre-treatment assessment, photographs, consent and scheduled follow-up reduce both complications and disputes.
- The evidence base is mostly narrative reviews and case series, so protocols should follow local guidance and clinical judgement.
What Causes Eyelid Ptosis After Botulinum Toxin?
The leading explanation is that toxin reaches the levator palpebrae superioris, the muscle that lifts the upper lid. A 2026 narrative review in Cureus proposes diffusion through the orbital septum, septal dehiscence, or passage via the supraorbital and supratrochlear foramina. Dr Martyn King, writing in the Journal of Clinical and Aesthetic Dermatology, adds that toxin may also track along tributaries of the superior ophthalmic vein.
Risk factors named in these sources include injections near the supraorbital margin (especially along the mid-pupillary line), higher volumes or deeper injections, older age with levator atrophy or septal attenuation, heavy or short brows, and an inexperienced injector. Dilution, product quality, placement and dose are also listed as treatment-related factors.
How Common Is Ptosis After Botulinum Toxin?
Published figures range from under 1% to around 14%, depending on the series and the injector's experience. The Cureus review reports about 1–14% after glabellar injections, falling below 1% with experienced injectors. A 10,577-report pharmacovigilance analysis cited in the same review found eyelid and brow ptosis together made up 6.1% of cosmetic adverse events.
| Source | Reported figure | Context |
|---|---|---|
| Freixo & Camões-Barbosa, Cureus 2026 | ~1–14%; <1% with experienced injectors | After glabellar injections, narrative reviews and series |
| Same review (pharmacovigilance) | 6.1% of adverse events | Eyelid and brow ptosis combined, 10,577 cosmetic reports |
| King, J Clin Aesthet Dermatol 2016 | 5.4% (12/263) in an Allergan FDA study | Many cases attributed to inexperienced injectors |
The authors of the 2026 review rate the overall evidence as low-level, so these numbers should be read as ranges rather than precise risk estimates.
How Do You Prevent Eyelid Ptosis During Injection?
Prevention is mainly technique and selection: respect the anatomical danger zones, dose conservatively and treat the glabella and forehead in balance. King's practical guidance, drawn from clinical experience, includes the following points.
Before treatment
- Take a full history, including prior facial surgery, myasthenia gravis, multiple sclerosis, prior ptosis or Bell's palsy, and obtain consent that names ptosis as a risk.
- Assess pre-existing brow asymmetry and frontalis resting tone, and take baseline photographs.
- If the brows descend when the patient sits upright, looks forward and closes the eyes, avoid treating the forehead lines.
During treatment
- Keep glabellar injections at least 1 cm above the brow and not lateral to the mid-pupillary line.
- Use digital pressure over the supraorbital rim with the non-injecting hand during corrugator injection, and angle the needle superiorly, away from the orbit.
- Inject forehead points at least 2 cm above the brow (4 cm in older patients), and treat glabella and forehead together, particularly over age 50.
- For crow's feet, do not inject medial to the mid-pupillary line or within 1 cm of the orbital margin.
One study cited by King associated intradermal forehead injection with lower ptosis rates without loss of effect. Reconstitution and storage discipline also support predictable dosing; see our Nabota dosage, dilution and storage handling guide and the botulinum toxin cold chain checklist.
How Is Toxin-Related Eyelid Ptosis Treated?
Mild cases may be managed with reassurance and observation, while moderate cases are commonly treated with topical alpha-adrenergic agonists that stimulate Müller's muscle. Neither source claims eye drops reverse the toxin effect; they provide partial compensatory lid elevation while the toxin wears off.
| Option | Reported use | Notes |
|---|---|---|
| Apraclonidine 0.5% | 1–2 drops, three to four times daily (Cureus review); three times daily (King) | About 1–2 mm lid elevation; check for susceptibility to closed-angle glaucoma; possible miosis and tachyphylaxis |
| Oxymetazoline 0.1% | Once daily in trials; FDA-approved 2020 for acquired blepharoptosis in adults | MRD gains of about 0.6–1.1 mm in trials not limited to toxin-induced ptosis |
| Phenylephrine 2.5%, naphazoline, brimonidine | Alternatives depending on availability and ocular comorbidity | Phenylephrine may cause systemic effects and rebound hyperaemia |
| Pretarsal toxin (expert use only) | Small uncontrolled series | Limited evidence; reserved for experienced practitioners |
Physical modalities such as electrical stimulation or lymphatic drainage are mentioned in some reports but are unsupported by robust evidence. Lower-lid ptosis has no specific treatment and usually resolves within weeks; prompt ophthalmology referral is advised if ectropion develops, to prevent exposure keratitis.
How Do You Tell Eyelid Ptosis From Brow Ptosis?
Eyelid ptosis is a lowered lid margin with difficulty fully opening the eye, while brow ptosis is a lowered eyebrow. King describes eyelid ptosis as measured by margin reflex distance (MRD) and brow ptosis as assessed by brow position and frontalis resting tone. Brow ptosis is usually linked to forehead treatment, or glabellar treatment without balanced frontalis treatment.
The distinction matters because the management differs. Brow problems may be corrected by experienced practitioners with small, targeted toxin adjustments, whereas eyelid ptosis is addressed with drops and time. Document MRD and photographs at every follow-up, and refer persistent cases to a more experienced colleague.
How Long Does Ptosis Last and When Does It Appear?
Onset is typically within the first week or two, and most cases settle within weeks. The Cureus review gives onset up to about 7–10 days and resolution of most cases within 2–4 weeks, although one table in that review states 6–12 weeks. King reports presentation at 3–7 days, eyelid ptosis often settling in 3–4 weeks and brow ptosis in about six weeks, and notes ptosis may last the full duration of toxin effect.
Because published timelines differ, counsel patients that duration varies and arrange a follow-up visit rather than promising a fixed recovery date.
What Should Clinics Check About Their Toxin Supply?
Predictable outcomes depend on correct dilution, verified product and an unbroken cold chain. Sources list product quality and dilution among factors affecting ptosis risk. Clinics should confirm authenticity using a structured process (see our counterfeit checklist), understand unit differences between brands (Dysport vs Botox units), and keep batch records. HolyPath supplies certified Korean and international toxins, including Dysport 500 Units (abobotulinumtoxinA, Ipsen). For related complication protocols, read our HA filler vascular occlusion guide.
Frequently Asked Questions
How common is eyelid ptosis after botulinum toxin injections?
Reported rates vary widely. A 2026 narrative review cites roughly 1–14% after glabellar injections in published reviews and case series, falling below 1% with experienced injectors. An older Allergan study cited by Dr Martyn King reported 5.4% (12 of 263). Differences in technique, dose and patient selection explain much of the spread.
How long does toxin-related eyelid ptosis last?
It is generally temporary. Sources describe onset within about 3–10 days and resolution of most cases within 2–4 weeks, with brow ptosis taking around six weeks. Some cases last longer, and ptosis can persist for the full duration of the toxin's effect, so documented follow-up is important.
Which eye drops are used for botulinum toxin ptosis?
Apraclonidine 0.5% is the most commonly cited option, usually one to two drops three to four times daily in the sources reviewed, acting on Müller's muscle for about 1–2 mm of lid elevation. Oxymetazoline 0.1% is FDA-approved for acquired blepharoptosis. Prescribing decisions belong to the treating clinician after an ophthalmic history.
Is eyelid ptosis the same as brow ptosis?
No. Eyelid ptosis is drooping of the upper lid from weakened levator palpebrae superioris, often after glabellar injection. Brow ptosis is a lowered eyebrow, usually linked to forehead treatment or glabellar treatment without balanced frontalis dosing. They are assessed differently, using margin reflex distance and brow position respectively.
Can the choice of toxin product cause ptosis?
Ptosis is a recognised class risk with all botulinum toxin type A products. Factors cited in the literature include dilution, dosage, placement and injector experience. Product authenticity and correct cold-chain handling also matter for predictable results, which is why clinics should buy only from verified, documented suppliers.
Conclusion
Eyelid ptosis is uncommon in experienced hands, usually temporary and largely preventable through anatomy-led technique, careful selection and clear consent. Clinics and distributors building toxin portfolios should pair clinical training with verified sourcing and documented handling. To discuss wholesale supply, contact the HolyPath team via our inquiry page.
References
- Freixo S, Camões-Barbosa A. Management of Complications Following Botulinum Toxin Facial Injections: A Narrative Review. Cureus 2026;18(1):e100675
- King M. Management of Ptosis. J Clin Aesthet Dermatol 2016;9(12):E1–E4
This article is for informational purposes for licensed medical professionals and distributors. It is not medical advice. Treatments should be performed only by qualified practitioners in accordance with local regulations.